Australia's most trusted
source of pharma news
Saturday, 19 July 2025
Posted 16 July 2025 AM
A Phase 1b trial of a CAR T combination treatment for people who have failed multiple lines of therapy for a blood cancer is set to be expanded to more niche indications after an additional two patients achieved a complete response (CR) rate.
Sydney-based Imugene is running the trial of its off-the-shelf CAR T therapy azercabtagene zapreleucel (azer-cel) in combination with chemotherapy and interleukin 2 in treating released/refractory diffuse large B-cell lymphoma (DLBCL).
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.